342 related articles for article (PubMed ID: 30201597)
1. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
Eckman MH; Ward JW; Sherman KE
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):930-939.e9. PubMed ID: 30201597
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
Rein DB; Smith BD; Wittenborn JS; Lesesne SB; Wagner LD; Roblin DW; Patel N; Ward JW; Weinbaum CM
Ann Intern Med; 2012 Feb; 156(4):263-70. PubMed ID: 22056542
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
[TBL] [Abstract][Full Text] [Related]
4. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
McEwan P; Ward T; Yuan Y; Kim R; L'italien G
Hepatology; 2013 Jul; 58(1):54-64. PubMed ID: 23389841
[TBL] [Abstract][Full Text] [Related]
5. Assessing the cost-effectiveness of hepatitis C screening strategies in France.
Deuffic-Burban S; Huneau A; Verleene A; Brouard C; Pillonel J; Le Strat Y; Cossais S; Roudot-Thoraval F; Canva V; Mathurin P; Dhumeaux D; Yazdanpanah Y
J Hepatol; 2018 Oct; 69(4):785-792. PubMed ID: 30227916
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States.
Tatar M; Keeshin SW; Mailliard M; Wilson FA
JAMA Netw Open; 2020 Sep; 3(9):e2015756. PubMed ID: 32880650
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
8. Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection.
Nguyen J; Barritt AS; Jhaveri R
J Pediatr; 2019 Apr; 207():90-96. PubMed ID: 30738661
[TBL] [Abstract][Full Text] [Related]
9. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of screening for chronic hepatitis C infection in the United States.
Eckman MH; Talal AH; Gordon SC; Schiff E; Sherman KE
Clin Infect Dis; 2013 May; 56(10):1382-93. PubMed ID: 23392392
[TBL] [Abstract][Full Text] [Related]
11. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.
Younossi Z; Blissett D; Blissett R; Henry L; Younossi Y; Beckerman R; Hunt S
Liver Int; 2018 Feb; 38(2):258-265. PubMed ID: 28719013
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs.
Schackman BR; Gutkind S; Morgan JR; Leff JA; Behrends CN; Delucchi KL; McKnight C; Perlman DC; Masson CL; Linas BP
Drug Alcohol Depend; 2018 Apr; 185():411-420. PubMed ID: 29477574
[TBL] [Abstract][Full Text] [Related]
13. The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit.
Selvapatt N; Ward T; Harrison L; Lombardini J; Thursz M; McEwan P; Brown A
Liver Int; 2017 Mar; 37(3):345-353. PubMed ID: 27566283
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy.
Ruggeri M; Romano F; Basile M; Coretti S; Rolli FR; Drago C; Cicchetti A
Appl Health Econ Health Policy; 2018 Oct; 16(5):711-722. PubMed ID: 30039348
[TBL] [Abstract][Full Text] [Related]
15. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
[TBL] [Abstract][Full Text] [Related]
16. Modelling the Impact and Cost-effectiveness of Extended Hepatitis C Virus Screening and Treatment with Direct-acting Antivirals in a Swiss Custodial Setting.
Girardin F; Hearmon N; Castro E; Negro F; Eddowes L; Gétaz L; Wolff H
Clin Infect Dis; 2019 Nov; 69(11):1980-1986. PubMed ID: 30715266
[TBL] [Abstract][Full Text] [Related]
17. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.
Linas BP; Wong AY; Schackman BR; Kim AY; Freedberg KA
Clin Infect Dis; 2012 Jul; 55(2):279-90. PubMed ID: 22491339
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States.
Chaillon A; Rand EB; Reau N; Martin NK
Clin Infect Dis; 2019 Nov; 69(11):1888-1895. PubMed ID: 30689769
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study.
Assoumou SA; Nolen S; Hagan L; Wang J; Eftekhari Yazdi G; Thompson WW; Mayer KH; Puro J; Zhu L; Salomon JA; Linas BP
Am J Med; 2020 Nov; 133(11):e641-e658. PubMed ID: 32603791
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of screening for hepatitis C in Canada.
Wong WWL; Tu HA; Feld JJ; Wong T; Krahn M
CMAJ; 2015 Feb; 187(3):E110-E121. PubMed ID: 25583667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
